Medicine (Apr 2022)

Pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus

  • Fan Yang, MD,
  • Youzi Dong, MD,
  • Baohua Li, MD,
  • Bobiao Ning, MD,
  • Quanlin Zhao, PhD

DOI
https://doi.org/10.1097/MD.0000000000029154
Journal volume & issue
Vol. 101, no. 17
p. e29154

Abstract

Read online

Abstract. Background:. Dipeptidyl-peptidase IV inhibitor (DPP-4i) is a common hypoglycemic medication in treating type 2 diabetes millitus. It has become widely utilized in clinical practice due to its ability to effectively manage blood glucose while posing a low risk of hypoglycemia and weight gain. However, there is no consensus on DPP-4i's pancreatic safety due to a paucity of clinical evidence. The safe event appears to be easily overlooked. This review aims to evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes mellitus using the standard pairwise and network meta-analysis methods. Methods:. MEDLINE, Embase, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials will be used to search for published literature on the pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus, and clinical trial registries will be used to look for unpublished trials. Two independent reviewers will screen literature for eligibility, extract available data, and assess the risk of bias. All divergences will be resolved after rechecking the source papers and further discussion among the reviewers with a complete consensus before inclusion. The risk of bias will be assessed by the Cochrane bias risk tool, and the quality of evidence will be interpreted by the GRADE Working Group approach. We will use STATA16.0 and WinBUGS1.4.3 for paired meta-analysis and Bayesian network meta-analysis. Results:. This study will evaluate the pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus. Conclusion:. This systematic review and network meta-analysis will evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes millitus. The findings of this study may supplement the evidence-based information on DPP-4i, improve existing understanding of this issue, and assist patients and clinicians in making better treatment decisions by raising their awareness of the problem. Protocol registration number:. INPLASY202230014.